NSPR (38) PLRZ (42) RVP (33) MODD (36) ⌘ Pro Terminal →

Picard Medical Inc. (PMI) — RQD Stock Rating Cockpit

$8.11 +12.17% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.27

Picard Medical Inc. (PMI) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $19.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.27 (+2.00%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PMI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY PMI SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 50.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+14/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$9.48+34.5% Next Q

Q2 (-2Q)

Grade B-$12.75-44.4% Next Q

Q3 (-1Q)

Grade C+$7.09+14.4% Next Q

Current

Grade C-$8.11+0.5% Hist 90D α

Trajectory: B- (69) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PMI Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, PMI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($7.18) or 200D SMA ($27.52) invalidates the momentum regime and cuts Target Base ($8.22) toward Bear Floor ($6.41).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PMI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PMI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

50.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE3% OF RANGE

L: $3$8.11H: $208

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on PMI

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (63)

23/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like PMI

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PMI Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PMI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -64.35%▼ DESCENDING CHANNEL

2026-10-30O $8.15H $8.81L $7.74C $8.11VOL 56.1K

RES: $18.04SUP: $0.36SMA50: $7.18SMA200: $27.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PMI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PMI Butterfly Map → + Track PMI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PMI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PMI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PMI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PMI)

Health Care Rank #196 of 1016 ⚔️ NSPR vs PMI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PMI vs. NSPR, PLRZ, RVP, MODD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Picard Medical Inc. (PMI) ranks #196 by composite RQD confidence (61/100, grade C-) and #834 by equity capitalization ($19.9M). Within this direct 5-issuer industry benchmark cohort, PMI leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. PMI currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PMI ACTIVE Picard Medical Inc.	C-	61/100	—	—	—	+12.17%	$19.9M	Benchmark Subject
NSPR InspireMD Inc.	D-	38/100	—	29.5%	-35.0%	-3.55%	$21.0M	/nspr-vs-pmi →
PLRZ Polyrizon Ltd.	D-	42/100	—	—	-25.1%	+4.57%	$21.9M	/plrz-vs-pmi →
RVP Retractable Technologies Inc.	E	33/100	—	0.1%	-23.3%	-1.15%	$17.3M	/rvp-vs-pmi →
MODD Modular Medical Inc.	D-	36/100	—	—	-35.0%	-9.95%	$16.3M	/modd-vs-pmi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002030617

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Picard Medical Inc. (PMI) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, PMI closed FY2025 with $22.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$22.5M	—

3. PMI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PMI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Picard Medical Inc. (NYSE: PMI) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $8.11 (+12.17% 1D, market cap $19.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PMI ranks #196 in composite RQD confidence.

How does PMI compare to NSPR and PLRZ in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PMI carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NSPR (InspireMD Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M) and PLRZ (Polyrizon Ltd.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -25.1%, cap $21.9M). Among the 5-stock peer group, PMI leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PMI?

Per PMI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002030617), Picard Medical Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $22.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PMI trading relative to its 50-day, 200-day, and 52-week technical levels?

PMI last traded at $8.11 (+12.17% on volume of 71,134 shares), positioning the stock +12.95% above its 50-day simple moving average ($7.18) and -70.53% below its 200-day simple moving average ($27.52). Across its 52-week range of $2.65 to $208.00, PMI sits at the 2.7% percentile with a 14-day RSI of 50.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.10 to $9.12).

PMI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PMI stock right now?

Picard Medical Inc. (PMI) currently earns a Roarable Rating of C- (Hold — HOLD) with 61/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is PMI's 12-month price target and RQD AI Jury consensus?

PMI's 12-month base price target is $8.22 (range $6.41 to $218.4), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PMI RQD Cockpit PMI 12M Forecast PMI Earnings & Move PMI Dividends & DRIP PMI Insiders & 13F PMI Whale Options PMI Profit Sankey PMI News & Why